Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Parabilis Medicines, Inc./ 8-K

Current Report · Items 7.01 · 8-K

Parabilis Medicines, Inc.

PBLSNASDAQEQUITYCurrent

Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Parabilis Medicines, Inc. is updating its guidance to reflect its intention to present updated clinical data from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.…

Filed Sep 15, 2026Accepted Sep 15, 2026, 4:15 PM EDTCIK 1657677Accession 0001193125-26-391952
View company →Permanent SEC source ↗
Share

Company context

We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.

Current securities

PBLSNASDAQ · EQUITY · Current

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 2, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureAug 25, 2026
  3. SCHEDULE 13G filingAug 14, 2026
  4. 10-Q filingAug 13, 2026
  5. Results of Operations and Financial Condition · Regulation FD DisclosureAug 13, 2026

Disclosure sections

Items 7.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Parabilis Medicines, Inc. is updating its guidance to reflect its intention to present updated clinical data from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The presentation is scheduled for Saturday, October 24 during a sarcoma-focused Proffered Paper session beginning at 2:45pm CEST (8:45am ET). The information included under Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.